0001123292-16-002600.txt : 20160817 0001123292-16-002600.hdr.sgml : 20160817 20160817141924 ACCESSION NUMBER: 0001123292-16-002600 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150805 FILED AS OF DATE: 20160817 DATE AS OF CHANGE: 20160817 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zynerba Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001621443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260389433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 W. LANCASTER AVENUE STREET 2: SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 BUSINESS PHONE: 484-581-7505 MAIL ADDRESS: STREET 1: 80 W. LANCASTER AVENUE STREET 2: SUITE 300 CITY: DEVON STATE: PA ZIP: 19333 FORMER COMPANY: FORMER CONFORMED NAME: Zynerba Pharmeceuticals, Inc. DATE OF NAME CHANGE: 20141003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hanlon Suzanne M. CENTRAL INDEX KEY: 0001631682 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37526 FILM NUMBER: 161838262 MAIL ADDRESS: STREET 1: C/O ZYNERBA PHARMACEUTICALS, INC. STREET 2: 170 N. RADNOR-CHESTER RD CITY: RADNOR STATE: PA ZIP: 19087 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2015-08-05 0001621443 Zynerba Pharmaceuticals, Inc. ZYNE 0001631682 Hanlon Suzanne M. C/O ZYNERBA PHARMACEUTICALS, INC 80 W. LANCASTER AVENUE, SUITE 300 DEVON PA 19333 0 1 0 0 Sec, General Counsel & VP HR Common Stock 2015-08-05 4 P 0 3000 17.92 A 3000 I By spouse Common Stock 2016-08-16 4 S 0 3000 10.53 D 0 I By spouse Common Stock 39893 D The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.47 to $10.70, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. /s/ Suzanne M. Hanlon 2016-08-17